ArticleCureus2026
Evaluating the Feasibility and Safety of Daily Inter-facility Travel for Proton Beam Therapy During Chemotherapy-Induced Myelosuppression in Children With Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProton beam therapy (PBT) is widely used in pediatric oncology to reduce radiation exposure to normal tissues and mitigate late adverse effects. In Japan, the limited availability of centers that can provide pediatric PBT with sedation and/or concurrent chemotherapy often necessitates inter-facility travel. However, the safety of daily inter-facility travel for PBT during chemotherapy-induced myelosuppression has not been well evaluated. We assessed the feasibility and safety of this model in Nagano Prefecture.
methodsWe conducted a retrospective cohort study using data from three hospitals in Nagano Prefecture (Nagano Children's Hospital, Shinshu University Hospital, and Aizawa Hospital) from June 2011 to August 2021. Patients who underwent PBT at a proton center with daily inter-facility travel during chemotherapy-induced myelosuppression were compared with patients who received conventional X-ray therapy (XRT) without transfer. Myelosuppression was defined as an absolute neutrophil count <500/µL. We extracted data on infection prophylaxis, febrile neutropenia (FN), documented infections, radiotherapy interruptions, and other adverse events, including events related to inter-facility travel or sedation.
resultsAmong 166 pediatric patients who received radiotherapy, 55 underwent PBT and 111 underwent XRT. Of these, 20 patients in the PBT group and 18 in the XRT group developed myelosuppression during concurrent chemoradiotherapy and were included in the analysis. Treatment interruptions were more frequent in the PBT group, but most lasted one to two days. FN was the most common immediate reason for interruption. There were no significant differences between groups in the incidence of FN or documented infections, and no adverse events were clearly attributable to inter-facility travel or sedation in the PBT group.
conclusionsIn this cohort, daily inter-facility travel for pediatric PBT during chemotherapy-induced myelosuppression was feasible. Although brief treatment interruptions were more frequent in the PBT group, infectious outcomes were comparable to those of patients receiving XRT without transfer, and no travel- or sedation-related adverse events were identified. Coordinated multidisciplinary protocols may help minimize avoidable interruptions while maintaining safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.